Promising models for cancer-induced cachexia drug discovery

Area of Science:

• Oncology
• Translational Medicine
• Pharmacology

Background:

• Cachexia is a frequent, multifactorial syndrome in cancer patients, negatively impacting quality of life, treatment tolerance, efficacy, and survival.
• Current treatment options for cancer cachexia (CC) are limited to addressing the underlying malignancy.
• The poor understanding of CC pathophysiology complicates clinical trial design, highlighting the need for robust animal models.

Purpose of the Study:

• To review available animal models for cancer cachexia (CC).
• To evaluate the utility and limitations of these models in translational studies.
• To provide expert opinion on optimizing the use of CC models for drug discovery and development.

Main Methods:

• Literature review of existing cancer cachexia animal models.
• Analysis of model characteristics, signaling pathways, and translational relevance.
• Consideration of experimental design factors, including the use of chemotherapy.

Main Results:

• Various animal models exist for studying cancer cachexia (CC), each with unique strengths and weaknesses.
• Human xenograph models require immunocompromised mice, potentially limiting translational applicability.
• Chemotherapy can induce or alter cachexia, necessitating its inclusion in experimental designs.

Conclusions:

• Multiple CC models are recommended to address the heterogeneity of cachexia in patient subgroups.
• Careful consideration of model limitations, particularly immune status in xenografts, is essential.
• Integrating standard chemotherapy into experimental designs can provide a more comprehensive understanding of CC and therapeutic responses.